KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-Current Deffered Revenue: 2013-2019

  • Xenon Pharmaceuticals' Non-Current Deffered Revenue was N/A to $709,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $709,000, marking a year-over-year change of. This contributed to the annual value of $709,000 for FY2019, which is N/A change from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Non-Current Deffered Revenue stood at $709,000 for Q4 2019, which was up 332.32% from $164,000 recorded in Q2 2015.
  • Xenon Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $709,000 for Q4 2019, and its period low was $164,000 during Q2 2015.
  • In the last 1 years, Xenon Pharmaceuticals' Non-Current Deffered Revenue had a median value of $709,000 in 2019 and averaged $709,000.